Drug Overview

Onatasertib (also known by its developmental code CC-90010) is an investigational, orally bioavailable, small-molecule inhibitor of the Bromodomain and Extra-Terminal (BET) family of proteins. It is specifically designed to bind to the bromodomains of BET proteins (including BRD2, BRD3, and BRD4), preventing them from interacting with acetylated histones on DNA.

In the clinical landscape of March 2026, onatasertib is recognized as a potent “epigenetic modulator.” By blocking the BET proteins, the drug effectively “turns off” the expression of critical oncogenes—such as MYC and BCL2—that cancer cells use to grow, survive, and resist treatment. Developed by Bristol Myers Squibb (formerly Celgene), it is being evaluated for its ability to cross the blood-brain barrier, making it a primary candidate for treating aggressive brain tumors like glioblastoma and other advanced solid tumors that have become resistant to standard therapies.

Generic Name: Onatasertib.
Code Name: CC-90010.
Drug Class: BET (Bromodomain and Extra-Terminal) Inhibitor; Epigenetic Modulator.
Mechanism: Competitive inhibition of the acetyl-lysine binding pocket of BET proteins to suppress oncogene transcription.
Route of Administration: Oral (Capsule).
FDA Approval Status: Investigational. As of March 2026, onatasertib is not FDA-approved. It has been granted Orphan Drug Designation for the treatment of glioblastoma and is currently in Phase 1 and Phase 2 clinical trials.

What Is It and How Does It Work? (Mechanism of Action)

Onatasertib works by disrupting the “reading” of the cancer cell’s genetic code.

1. Epigenetic “Reader” Inhibition

In a cell, DNA is wrapped around proteins called histones. When these histones are “acetylated” (marked with an acetyl group), it signals the cell to “read” the nearby genes. BET proteins (like BRD4) act as the “readers” that bind to these marks and recruit the machinery needed to turn genes on.

The Blockade: Onatasertib sits in the binding pocket of the BET protein.
The Result: The BET protein can no longer attach to the DNA, effectively “silencing” the genes in that area.

2. Suppression of MYC and BCL2

Cancer cells are often “addicted” to specific proteins for survival.

MYC Suppression: MYC is a master regulator that drives rapid cell division. Onatasertib significantly lowers MYC levels, causing the cancer cell to stop growing.
BCL2 Suppression: BCL2 is a protein that prevents cells from dying. By lowering BCL2, onatasertib “lowers the shield” and makes the cancer cell vulnerable to apoptosis (programmed cell death).

3. Crossing the Blood-Brain Barrier

One of the most significant features of onatasertib is its pharmacokinetic profile, which allows it to penetrate the central nervous system (CNS). This makes it one of the few epigenetic drugs capable of reaching the high concentrations needed to treat tumors deep within the brain.

Clinical Indications and Research Status (2026)

Onatasertib is being evaluated across several high-unmet-need areas in oncology:

Relapsed/Refractory Glioblastoma (GBM): This is the lead indication. It is being studied in the Phase 2 CC-90010-GBM-001 trial for patients whose brain tumors have returned after surgery and radiation.
Diffuse Large B-cell Lymphoma (DLBCL): Investigated for patients with “double-hit” or “triple-hit” lymphomas, which are characterized by high levels of MYC and BCL2.
Advanced Solid Tumors: Evaluated in Phase 1 trials for patients with metastatic prostate cancer, triple-negative breast cancer (TNBC), and small-cell lung cancer (SCLC).
Combination Therapies: Research in 2025–2026 has focused on pairing onatasertib with temozolomide (chemo) or immunotherapy to see if “epigenetic priming” can make standard treatments more effective.

Dosage and Administration Protocols

As an investigational drug, onatasertib dosing is strictly managed within clinical trial protocols (such as the CC-90010-ST-001 study).

Treatment Parameter	Investigational Specification (2025–2026)
Route	Oral (Capsule).
Dosing Schedule	Often administered on an intermittent schedule (e.g., 3 days on, 4 days off) to minimize toxicity.
Standard Dose	Often studied at 30 mg to 45 mg once daily on dosing days.
Cycle Length	Administered as part of a 21-day or 28-day cycle.
Fasting Status	Usually taken on an empty stomach for better absorption.

Clinical Efficacy and Research Results

As of early 2026, results from Phase 1/2 trials have provided significant biological proof-of-concept:

CNS Activity: Clinical data has confirmed that onatasertib reaches therapeutic levels in the cerebrospinal fluid (CSF) of glioblastoma patients.
Tumor Stabilization: In advanced solid tumor trials, the drug has shown the ability to induce prolonged Stable Disease (SD) in patients who had failed multiple prior lines of chemotherapy.
Pharmacodynamic Markers: Biopsies have confirmed a significant decrease in the expression of the MYC gene in patient tumor tissue after just one week of treatment.

Safety Profile and Side Effects

The primary side effects of onatasertib are related to its effect on healthy, rapidly dividing cells like those in the bone marrow and gut.

1. Hematologic Toxicity (Dose-Limiting)

Because BET proteins are needed for normal blood cell production, onatasertib can cause:

Thrombocytopenia: A drop in blood platelets, which can increase the risk of bruising or bleeding. (Reported in over 30% of patients).
Anemia and Neutropenia: A drop in red and white blood cells.

2. Gastrointestinal Issues

Nausea and Vomiting: Usually mild and managed with standard anti-emetics.
Dysgeusia: A change in the sense of taste (e.g., a metallic taste), which is a common feature of many epigenetic drugs.
Fatigue: General systemic tiredness.

3. Serious Risks:

Hyperbilirubinemia: A transient increase in liver markers, requiring regular monitoring.
Infection Risk: Due to the drop in white blood cell counts (neutropenia).

Research Areas

In the fields of Stem Cell and Regenerative Medicine, onatasertib is being used to study “Cellular Reprogramming.” Researchers are investigating how BET inhibition can “reset” the epigenetic state of Cancer Stem Cells (CSCs), potentially making them less aggressive and more sensitive to chemotherapy. In 2026, there is also intense focus on “Synthetic Lethality.” Scientists are pairing onatasertib with PARP inhibitors (like olaparib) to see if blocking BET proteins creates a “BRCA-like” defect in tumor cells, making them uniquely vulnerable to DNA-damaging drugs.

Patient Management and Practical Recommendations

Pre-treatment Requirements:

Baseline Blood Work: Comprehensive CBC and metabolic panel (especially liver enzymes and platelets).
Neurological Baseline: For GBM patients, a thorough assessment of cognitive and motor function.

“Do’s and Don’ts” List:

DO keep a strict log of your “days on” and “days off” the drug; the intermittent schedule is critical to allow your bone marrow to recover.
DO report any “unusual bruising” or “petechiae” (tiny red spots on the skin) immediately, as these are signs of low platelets.
DON’T take any new over-the-counter medications that can affect bleeding (like aspirin or ibuprofen) without consulting your oncologist.
DON’T ignore a sudden metallic taste or loss of appetite; your oncology team can provide “taste-masking” strategies or nutritional support.

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. Onatasertib (CC-90010) is an investigational agent and is not approved by the U.S. FDA for commercial use. Access is limited exclusively to registered clinical trials. Always consult with a qualified oncologist regarding your specific diagnosis and eligibility for research participation.